SGEN Seattle Genetics, Inc.

59.12
+0.26  (0.44%)
Previous Close 58.86
Open 58.95
Price To book 12.58
Market Cap 8.37B
Shares 141,552,000
Volume 793,833
Short Ratio 8.71
Av. Daily Volume 1,398,800

SEC filingsSee all SEC filings

  1. 8-K - Current report 162071038
  2. 8-K - Current report 162069674
  3. 8-K - Current report 162056746
  4. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 161984924
  5. CT ORDER - Confidential treatment order 161970408

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 trial placed on clinical hold - announced December 27, 2016.
Vadastuximab Talirine (SGN-CD33A)
Frontline Acute Myeloid Leukemia (AML)
Approved August 18, 2015 under priority review
ADCETRIS - AETHERA
Post-transplant Hodgkin lymphoma (HL) cancer
Phase 3 initiated May 2016. Enrollment ongoing as of October 2016.
Vadastuximab Talirine (SGN-CD33A)
Acute myeloid leukemia (AML) - cancer
Phase 3 data due in 2017.
ADCETRIS in combination with chemotherapy ECHELON-1
Frontline Hodgkin lymphoma
Phase 2 trial initiated 3Q 2016.
SGN-CD19A
Frontline DLBCL cancer
Phase 3 enrollment completed November 2016. Data are due 2017 or 2018.
ADCETRIS in combination with chemotherapy - ECHELON-2
Frontline CD30-positive mature T-cell lymphomas - cancer
Phase 3 data released August 2016. sNDA to be filed 1H 2017.
ADCETRIS
Cancer - ALCANZA trial for relapsed CD30-positive cutaneous T-cell lymphoma

Latest News

  1. IMPORTANT SHAREHOLDER ALERT: Goldberg Law PC Announces a Class Action Lawsuit against Seattle Genetics, Inc. and Advises Investors with Losses to Contact the Firm
  2. SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Seattle Genetics, Inc. (SGEN) and Lead Plaintiff Deadline - March 13, 2017
  3. SHAREHOLDER NOTICE: Lundin Law PC Announces an Investigation of Seattle Genetics, Inc. and Encourages Investors with Losses to Contact the Firm
  4. SHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Seattle Genetics Inc. (SGEN) To Contact Brower Piven Before The Lead Plaintiff Deadline
  5. SHAREHOLDER ALERT: Lundin Law PC Announces an Investigation of Seattle Genetics, Inc. and Encourages Investors with Losses to Contact the Firm
  6. SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Seattle Genetics, Inc. To Contact The Firm Before Lead Plaintiff Deadline
  7. SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Seattle Genetics, Inc. (SGEN) and Lead Plaintiff Deadline - March 13, 2017
  8. INVESTOR ALERT: Lundin Law PC Announces an Investigation of Seattle Genetics, Inc. and Encourages Investors with Losses to Contact the Firm
  9. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Seattle Genetics Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 13, 2017 – SGEN
  10. EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Seattle Genetics Inc. – SGEN
  11. Pomerantz Law Firm Announces the Filing of a Class Action against Seattle Genetics Inc. and Certain Officers – SGEN
  12. After ARIAD's Acquisition, These 3 Cancer Drug Stocks Could Be Next
  13. Biotech Industry Off to a Strong Start in 2017 Latest Reports on Seattle Genetics and Ionis Pharmaceuticals
  14. Friday’s 6 Biopharma Movers That Can’t Be Ignored
  15. Post Earnings Coverage as Ohr Pharma Reported Annual Results; Announced Closure of Public Offering
  16. Seattle Genetics Initiates Phase 1 Trial of SGN-CD352A for Patients with Relapsed or Refractory Multiple Myeloma
  17. Seattle Genetics Initiates Phase 1 Trial of SGN-CD352A for Patients with Relapsed or Refractory Multiple Myeloma
  18. SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Seattle Genetics, Inc. (SGEN)
  19. Forget Buffett — four unsung investment gurus are picking these eight stocks for 2017
  20. IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Seattle Genetics, Inc. and Advises Investors with Losses to Contact the Firm

SEC Filings

  1. 8-K - Current report 162071038
  2. 8-K - Current report 162069674
  3. 8-K - Current report 162056746
  4. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 161984924
  5. CT ORDER - Confidential treatment order 161970408
  6. 10-Q - Quarterly report [Sections 13 or 15(d)] 161956389
  7. 8-K - Current report 161955668
  8. 8-K - Current report 161933676
  9. 424B7 - Prospectus [Rule 424(b)(7)] 161933659
  10. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 161887619